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Abstract
Background: Clostridium difficile-associated disease (CDAD) is a serious nosocomial infection,
however few studies have assessed CDAD outcome in the intensive care unit (ICU). We evaluated
the epidemiology, clinical course and outcome of hospital-acquired CDAD in the critical care
setting.
Methods: We performed a historical cohort study on 58 adults with a positive C. difficile cytotoxin
assay result occurring in intensive care units.
Results: Sixty-two percent of patients had concurrent infections, 50% of which were bloodstream
infections. The most frequently prescribed antimicrobials prior to CDAD were anti-anaerobic
agents (60.3%). Septic shock occurred in 32.8% of CDAD patients. The in-hospital mortality was
27.6%. Univariate analysis revealed that SOFA score, at least one organ failure and age were
predictors of mortality. Charlson score ≥3, gender, concurrent infection, and number of days with
diarrhea before a positive C. difficile toxin assay were not significant predictors of mortality on
univariate analysis. Independent predictors for death were SOFA score at infection onset (per 1-
point increment, OR 1.40; CI95 1.13–1.75) and age (per 1-year increment, OR 1.10; CI95 1.02–
1.19).
Conclusion: In ICU patients with CDAD, advanced age and increased severity of illness at the
onset of infection, as measured by the SOFA score, are independent predictors of death.
Background
Clostridium difficile is a major cause of antibiotic associ-
ated diarrhea and colitis [1]. The incidence of infection
with this organism is increasing in hospitals worldwide,
consequent to the widespread use of broad-spectrum anti-
biotics [2].
Hospital-acquired C. difficile disease is associated with not
only antimicrobial use, but also advanced age, laxative
use, proton pump inhibitors, antineoplastic chemothera-
peutic agent use, renal insufficiency, and gastrointestinal
surgery or procedures [3,4].
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Over the past several years, numerous reports have been
published regarding CDAD in immunocompromised
patients (bone marrow transplantation, solid organ trans-
plantation, HIV infected patients and those with neutro-
penia), [5-9] as well as hospitalized patients in acute care
medical wards [10].
The clinical and financial impact of nosocomial CDAD, as
measured by the attributable cost and length of stay, is sig-
nificant [11]. However few studies have assessed CDAD
outcome in the intensive care unit (ICU) setting [12].
The purpose of this study was to evaluate the epidemiol-
ogy, clinical course and outcome of hospital-acquired
CDAD in the ICU setting.
Methods
Setting
The Virginia Commonwealth University Medical Center
(VCUMC) is an 820-bed tertiary care facility in Richmond,
Virginia. The hospital houses 9 intensive care units
(ICUs), including pediatric ICUs and a burn unit. Approx-
imately 30,000 patients are admitted annually. The study
was approved by the VCUMC Institutional Review Board
(IRB).
Study design
All ICU patients with a positive C. difficile toxin at VCU
Medical Center from January 2002 to August 2005 were
identified retrospectively using the electronic medical
microbiology record. This was followed by a retrospective
chart review. Each patient was only included once at the
time of the first C. difficile result. Patients older than 18
years of age were included in the analysis. At study entry,
we recorded patient age, gender, location (medical ICU or
surgical ICU), predisposing clinical conditions on admis-
sion, and colonoscopy or surgical procedures for CDAD.
Data on nosocomial infections were collected for 14 days
following the date of the first positive C. difficile toxin
result. Additionally, we collected data on the duration of
diarrhea before and after diagnosis and treatment of
CDAD. Antimicrobial exposure preceding the diagnosis of
CDAD and the interruption of antimicrobial treatment
due to CDAD were also collected. Colonization status
with methicillin-resistant S. aureus (MRSA) and vancomy-
cin-resistant enterococci (VRE) were identified by clinical
cultures during the time of study. Adverse outcomes
(organ failure and mortality) that occurred during the
hospital stay were recorded. The clinical condition of each
patient was classified daily according to systemic inflam-
matory response syndrome (SIRS) criteria [SIRS, sepsis,
severe sepsis or septic shock] and SOFA scores from two
days prior to the first positive stool C. difficile-toxin assay
through 14 days afterwards [13,14]. The Sequential Organ
Failure Assessment (SOFA) score, assesses the incidence
and severity of organ dysfunction in critically ill patients
[14]. The severity of underlying disease preceding CDAD
was classified using the Charlson weighted comorbidity
index [15].
Definitions
We defined a CDAD case as a patient with a positive stool
C. difficile cytotoxin assay result and diarrhea. Diarrhea
was defined as a change in bowel habit with ≥3 unformed
bowel movements per day for ≥2 days [10]. We defined
treatment failure as recurrence of diarrhea plus an addi-
tional stool specimen positive for C. difficile toxin or a
physician order for a second course of treatment for C. dif-
ficile. Concurrent infection detected during CDAD was
defined according to Centers for Disease Control and Pre-
vention (CDC) criteria [16]. P revious antibiotic treatment
was defined as an antibiotic prescribed for at least 48
hours in the 60 days prior to CDAD. The SOFA score was
used to assess disease severity [14]. Systemic Inflamma-
tory Response Syndrome (SIRS) was defined as two or
more of the following: (1) temperature >38°C or <36°C,
(2) heart rate >90 beats per minute, (3) respiratory rate
>20 breaths per minute or a PaCO2 <32 mmHg, or (4)
white blood cell count >12 × 109/L or <4 × 109/L or the
presence of more than 10% immature neutrophils.
The clinical condition of each patient with CDAD was
classified daily as SIRS, sepsis, severe sepsis or septic shock
using criteria previously published by the American Col-
lege of Chest Physicians/Society of Critical Care Medicine
(ACCP/SCCM) [13]. Sepsis was defined as SIRS associated
with C. difficile-associated diarrhea. Sepsis associated with
organ dysfunction, hypotension or systemic manifesta-
tions of hypoperfusion constituted severe sepsis. Septic
shock was defined as sepsis associated with hypotension
unresponsive to intravenous fluid challenge or the need
for a vasopressor agent. The presence of organ system fail-
ure was assessed using the criteria described by Fagon
[17]. Nosocomial infection was defined as an infection
that occurred >48 hours after hospital admission, an
infection that occurred <48 hours after admission to the
hospital in patients that had been hospitalized in the 3
weeks prior to the admission, or an infection that
occurred <48 hours after admission to the hospital in
patients that had been transferred from another hospital
or nursing home [16]. Treatment for CDAD was defined
as the receipt of metronidazole at a dosage of 250 mg 4
times per day or 500 mg 3 times per day for 10–14 days,
or oral vancomycin 125 mg 4 times per day for the same
duration.
Statistical analysis
Continuous variables were compared using the Student t
test for normally distributed variables and the Mann-
Whitney U test for non-normally distributed variables.
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Differences in proportions were compared using a Chi-
square test or Fisher exact test when appropriate. Alpha
was set at 0.05 and all tests of significance were two-tailed.
Variables significant for predicting mortality in univariate
analysis were entered into a logistic regression model.
When collinearity was identified between two variables in
a correlation matrix, the one with the greatest clinical rel-
evance associated with mortality was included in the final
multivariate analysis. The Hosmer and Lemeshow good-
ness-of-fit statistic was used to assess adequacy of the
model fit. Odds ratios with 95% confidence intervals were
calculated for independent variables associated with mor-
tality related to CDAD. All statistical analyses were done
using the Statistical Package for the Social Sciences soft-
ware (SPSS version 11.0, Chicago, IL, USA).
Results
Study population and patient characteristics. From 613
hospitalized patients with CDAD, a total of 70 patients
were identified at VCUMC ICUs during the study period.
Sixty-three patients (90%) were adults and 7 were pediat-
ric patients (10%). Of the adult patients, 5 (7.9%) had
incomplete medical records. The remaining 58 adult ICU
patients with CDAD were included in the analysis.
The median age was 55.5 years with an inter-quartile
range (IQR) from 43 to 64 years. Twenty-two patients
(37.9%) were over 60 years of age. The majority of
patients were from surgical ICUs (63.8%). The most fre-
quent admission diagnoses were trauma (22.4%), cardio-
vascular disease (20.7%), gastrointestinal diseases
(17.2%) and solid and haematologic malignancies
(12.1%). The mean interval between hospitalization and
CDAD infection was 16.8 ± 18.5 days. The median dura-
tion of hospitalization was 32.0 days (IQR = 16.7–68.2).
The mean duration of diarrhea before CDAD diagnosis
was 6.5 ± 7.0 days. The majority of patients (93.1%) were
receiving antimicrobial therapy before CDAD (Table 1).
The most frequently prescribed antimicrobials prior to
CDAD were anti-anaerobic agents considering piperacil-
lin-tazobactam, metronidazole, carbapenems, or clin-
damycin (60.3%), quinolones (43.1%), and intravenous
vancomycin (43.1%). Other prescribed antimicrobials
were also cephalosporins (36.2%) and aminoglycosides
(15.6%).
Sixty-two percent of patients (36/58) had a concurrent
infection; of these 50% (18/36) were bloodstream infec-
tions (BSIs), a sizable fraction of which (39.9%, 11/18)
were polymicrobial. The most frequent concurrent BSI
pathogens BSI were gram-negative bacteria (35.0%), fol-
lowing by coagulase-negative staphylococci (20.0%), and
Candida albicans (20.0%). Other isolated pathogens Ente-
rococcus spp (15.0%), Streptococcus viridans (5.0%) and
Candida glabrata (5.0%). No vancomycin-resistant entero-
cocci were detected. In approximately thirty-nine percent
of BSI patients (7/18), a 24 hours delay in the initiation of
appropriate antimicrobial therapy was observed.
Nearly all patients (98.3%) with CDAD received metron-
idazole as the initial antimicrobial treatment. Five
patients failed the first course of antimicrobial therapy
(8.6%); of these, two were treated with a second course of
metronidazole, one was treated with vancomycin and two
patients received both drugs (Table 1). The majority of
patients (84.5%) with CDAD received concurrent antimi-
crobial therapy; in 13 (22.4%) of these patients there was
no evidence of another infection. Two patients (3.4%)
underwent colonoscopy for CDAD, but no patients
required operative management. Almost one-third of
CDAD patients were colonized with MRSA or VRE
(31.0%).
Table 1: Characteristics of CDAD in ICU patients.
VARIABLES N %
Age, years
Median (IQR) 55.5 (43.0–64.0) -
≤65 47 81.0
>65 11 19.0
Male gender 35 60.3
Charlson index, median (range) 2 (0–8) -
Intensive care unit
Medical 21 36.2
Surgical 37 63.8
Diagnosis on admission
Trauma 13 22.4
Cardiovascular disease 12 20.7
Gastrointestinal disease 10 17.2
Neoplasm 7 12.1
Respiratory disease 6 10.3
Neurologic disease 4 6.9
Other 6 10.3
Interval between hospitalization and 
CDAD, mean days ± SD
16.8 ± 18.5 -
Length of hospital stay: median days 
(IQR)
32.0 (16.7–68.2) -
Days with diarrhea before positive C. 
difficile toxin assay, mean ± SD (range)
6.5 ± 7.0 (0–31) -
Received antimicrobial therapy prior 
to CDAD
54 93.1
Concomitant infection 36 62.1
Initial antibiotic treatment course
Metronidazole 57 98.3
None 1 1.7
Second antibiotic treatment course
Not required 53 91.4
Metronidazole 2 3.4
Vancomycin 1 1.7
Metronidazole and vancomycin 2 3.4
Continued to receive antimicrobial 
therapy after CDAD
49 84.5
Concurrent MRSA or VRE colonization 18 31.0
In-hospital mortality 16 27.6
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Clinical course
Septic shock occurred in 32.8% (19/58) of CDAD
patients. The maximal SIR (severe sepsis, septic shock or
death) occurred in 43.1% (25/58) during the 14 days fol-
lowing the first positive C. difficile toxin assay. No signifi-
cant difference was observed in maximal SIR score
between patients with CDAD only and those with concur-
rent nosocomial infection (31.8% vs. 50.0%, p = 0.17). A
statistically significant difference in SOFA scores was
observed between the survivors and non-survivors. The
14-day mortality was 17.2% (10/58) and the in-hospital
mortality was 27.6% (16/58).
Univariate analysis revealed that SOFA score, septic shock,
at least one organ failure (respiratory, cardiovascular,
renal, hematologic and hepatic) and age were significant
predictors of mortality (table 2). Charlson score ≥3, gen-
der, other concurrent nosocomial infections, and days
from start of diarrhea to start of treatment for CDAD were
not significant predictors of mortality on univariate anal-
ysis. Variables significant for predicting mortality in uni-
variate analysis (age, SOFA score and at least one organ
failure) were entered into a logistic regression model (p <
0.05). Using this model, the following variables were
independent predictors for death (table 3): SOFA score at
CDAD infection onset (per 1-point increment; OR 1.40,
CI95 1.13–1.75) and age (per year; OR 1.10, CI95 1.02–
1.19).
Discussion
To better understand the epidemiology of CDAD infec-
tion in critically ill patients, we investigated its clinical
course and outcome in the intensive care units of a tertiary
care, academic medical center. Of the 58 ICU patients
with C. difficile colitis in our cohort study, a significant
proportion of these patients had concurrent infection
(62.1%). The majority of the pathogens associated with
nosocomial infections in our study cohort were gastroin-
testinal flora. This finding coupled with the relatively high
proportion of bloodstream infections that were pol-
ymicrobial suggest that the inflammation and disruption
of the colonic mucosa by CDAD provided a source of
entry for organisms into the bloodstream. Of note, 60%
of these patients had recently been treated with antimicro-
bials with significant activity against anaerobes, suggest-
ing an important protective role that anaerobes may play
in the intestinal flora. Similarly, disruption of the anaero-
bic gut flora has been shown to be a risk factor for VRE col-
onization [18], an epidemiologic finding that has been
experimentally validated in an animal model [19].
As more than a half of our C. difficile patients were co-
infected, findings predictably showed that a high propor-
tion of ICU CDAD patients had a maximal SIR (severe
sepsis, septic shock or death) during 14 days of follow-up.
However, no statistically difference was observed in max-
imal SIR between patients with CDAD only those with
CDAD and another infection (p = 0.17). One potential
explanation for this observation may have been the delay
in the introduction of specific antimicrobial therapy (met-
ronidazole or oral vancomycin) for patients with CDAD.
In our study, ICU patients were symptomatic with
diarrhea on average for 6.5 days prior to microbiologic
confirmation of the CDAD diagnosis and initiation of
therapy. In our study cohort, no patients required surgical
procedures as a result of CDAD. This is similar to another
report in which 2.5% of patients required emergency
colectomy [20].
Some studies have shown that treatment of CDAD with
metronidazole may lead to poor outcomes [21,22]. In our
study it was not our purpose to determine the efficacy of
metronidazole since we had multiple confounders such as
a high rate of co-infection, and some patients died before
Table 2: Univariate analysis of risk factors for in-hospital mortality in CDAD patients.
Died (n = 16) Recovered (n = 42) P
VARIABLES N % N %
Age, median years (IQR) 61.0 (56.0–69.0) - 53.0 (36.7–63.0) - 0.015
Male 7 43.8 28 66.7 0.11
Charlson ≥3 5 31.3 12 28.6 1.0
SOFA score at infection onset, median (IQR) 9.5 (6.0–14.5) - 4.0 (2.0–6.0) - <0.001
Other infections concurrently 11 68.8 25 59.5 0.52
Days of diarrhea prior to positive C. difficile toxin assay, median (IQR) 7.5 (2.0–14.2) - 3.0 (2.0–7.0) - 0.32
Organ failure (any) 16 100.0 28 66.7 0.01
Septic shock 12 75.0 7 16.7 <0.001
Respiratory failure 14 87.5 22 52.4 0.014
Renal failure 11 68.8 6 14.3 <0.001
Hematologic failure 3 18.8 3 7.1 0.33
Hepatic failure 5 31.3 3 7.1 0.03
IQR, Inter-quartile range
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completing metronidazole treatment. Almost one-fifth of
our patients received antibiotics in the absence of evi-
dence to suggest a concurrent infection. This observation
is particularly important as prior reports suggest that
unnecessary antibiotic use makes treatment of CDAD
more difficult and potentially less efficacious [2,3].
The crude mortality rate associated with C. difficile
diarrhea in our ICU population was high (27.6%). Simi-
larly, a prospective study at 12 Quebec hospitals of 1,073
patients with CDAD found a 30-day crude mortality rate
of 24.8% independent of being ICU or non-ICU patients
[23]. In this study, Loo et al. found that the age-specific
incidence of CDAD increased markedly after the age of 50
years and the attributable mortality rate increased after the
age of 60 years [23]. Pepin et al. have also found that
advanced age (≥65 years) is a risk factor for recurrence of
CDAD following treatment with metronidazole. By mul-
tivariate analysis, we demonstrated that for ICU patients
with CDAD, advanced age and a high SOFA score were
independent predictors of mortality. Prior studies have
identified advanced age as a risk factor for CDAD [11,24].
To our knowledge, no other studies have reported SOFA
score as a predictor for mortality in ICU patients with
CDAD.
The limitations of our study should be acknowledged.
First, we performed a retrospective cohort study; second,
we only evaluated patients during hospitalization. Thus,
we cannot comment on long term follow-up, including
relapse of diarrhea and mortality. Third, these findings
were specific for an ICU population in a tertiary care med-
ical center and thus may not be generalizable to a non-
ICU population. Fourth, as this study lacked controls, we
did not investigate risk factors for the development of
CDAD in our ICU population. Lastly, the study had a
small sample size thereby potentially resulting in a type II
error at the time of univariate and multivariate analysis.
Conclusion
CDAD is a serious nosocomial infection in ICU patients.
It is associated with a high mortality and a high rate of
nosocomial co-infection. As such, the management of
these infections remains challenging. In ICU patients with
CDAD, advanced age and increased severity of illness at
the onset of infection, as measured by the SOFA score, are
independent predictors of death.
Key messages
CDAD is not an infrequent infection with an usually late
diagnosis and therapy, and high potential comorbidity
and mortality. Almost one-fifth of our patients received
antibiotics in the absence of evidence to suggest a concur-
rent infection. Antibiotics are used in a indiscriminate way
in ICU. This observation is particularly important as prior
reports suggest that unnecessary antibiotic use makes
treatment of CDAD more difficult and potentially less
efficacious.
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